Gary Clark: Unfiltered
Insightful analysis on the financial currents, corporate maneuvers, and innovations defining our era.
About This Column
Gary Clark is a commentator and strategist exploring the intersection of finance and industrial transformation. Transitioning from his deep dive into corporate maneuvers, Gary now delivers daily dispatches on the broad forces defining the 2026 economic landscape - from the evolution of global supply chain finance to the impact of AI on asset allocation. With a reputation for providing "the story behind the numbers," he offers a unique lens on what drives market performance in a complex world. His writing is essential for anyone seeking to understand the "why" of today’s market to predict the "what" of tomorrow.
Displaying items 41-60 of 988 in total
Ahead's UK Foundry: A New Blueprint for Europe's AI Infrastructure Race?
Wah Fu's AI Gambit: From EdTech Losses to a High-Stakes Industrial Pivot
AI's 'Skynet' Moment and the Race to Build a Digital Fortress
EveryPlate's Playbook: Monetizing the Parental Mental Load
Crypto's Divergence: A New Market Logic or a Temporary Reprieve?
Nitya Capital's Pivot: From Foreclosure Scare to Aggressive Growth
Braveheart's $440M IPO: A Market Bellwether or Just a Biotech Bubble?
Femasys's $90M Lifeline: A High-Stakes Bet on Women's Health Innovation
South Korea's New Tourism Playbook: From Cultural Capital to Conversion
Clarus's $13M Profit Swing: A Tariff Windfall or a True Turnaround?
ARKO Petroleum's Twin Engines: Strong Earnings & a Game-Changing Deal
Beyond the Browser: How Seaweed is Tackling Agriculture's $100B Plastic Problem
Robocall Resurgence: The 4.3 Billion Call Assault on Economic Trust
Edinburgh's American Gambit: Culture, Capital, and a Calculated Risk
Gogo's Stormy Quarter: Military Growth Anchors High-Stakes Tech Pivot
West Shore Home's Tech Gambit: Betting on AI to Remodel an Industry
CI GAM’s Golden Handshake: A Windfall or a Strategic Signal?
CGPH's €104M Win: A Signpost in Europe's Shadow Banking Boom
Attovia’s $289M IPO: A High-Stakes Bet on Multi-Target Drug Platforms
